Arctic Aurora LifeScience passed this week 6 months in action, and can look back at volatile, but prosperous start to what aims to be a global leading healthcare fund. The team behind the fund, Ulrica Bjerke, Torbjørn Bjerke and Daniel Bolanowski, reports of a challenging environment to invest in, but have done so in a brilliant manner. The team has so far outperformed the funds index by nearly 9 per cent – and that only in half a year.
I’ve visited New York many times over the last 7 years. It is obviously a remarkable city and among other things, I’ve enjoyed long walks on Manhattan many times.
Playing a World Championship match seemingly twist perceptions and reduce outside sense impressions to the point that I felt I was experiencing a different city this time. The utter joy and relief of match victory will always make the thought of New York bring back fond memories. Nevertheless, I already look forward to be back in the city in a more normal setting as a visitor.
As in the Sochi-match, Magnus Carlsen himself will not be blogging during the ongoing World Championship match against challenger Sergey Karjakin, Russia. On behalf of Magnus and his team the undersigned will share some impressions instead.
The last year has been volatile for the pharmaceutical and biotech sectors, with a number of market corrections of the stocks in the sector. The reason has been the US Election and the democratic campaign, where Secretary Clinton went after the pharmaceutical companies and the drug prices in the US. US is by far the market dominating the world pharmaceutical market, hence US drug pricing is important for the sector outlook. The unexpected outcome of the election with the Republicans dominating all offices, takes the immediate issue of regulating drug off the agenda and the market traded up the sector immediately.